Evaluating the effects of Moringa oleifera on atherogenic lipoprotein indices of HIV infected Nigerian adults on tenofovir-based antiretroviral regimen

Chinwe F. Anyanwu, Wolie A. Obianime, Iyeopu M. Siminialayi, Eric O. Aigbogun


Background: The administration of tenofovir (TDF) based (tenofovir/ lamivudine/efavirenz) antiretroviral regimen for the management of HIV has remained a concern to both clinicians and patients, thus necessitating the need for suitable supplement for the management of ART induced metabolic abnormalities. The study evaluated the effects of Moringa supplementation on the atherogenic lipoprotein indices of HIV patients on TDF-based regimen at the University of Port Harcourt Teaching Hospital, Rivers State, Nigeria.

Methods: The study was designed as a time dependent investigation structured into 3 visits, visit 1 (cross sectional, baseline), visit 2 (4 weeks after administration) and visit 3 (12 weeks post administration). Subjects recruited (140) into this study comprised of two groups, TDF-M (n=56, administered Moringa Supplement) and TDF-NM (n=84, no supplement).

Results: At baseline, more than 50% of the patients had at least one abnormal atherogenic lipoprotein indices (Log (TC/HDL-C) = 85.7%, TC/HDL-C=58.5% and LDL-C/HDL-C=51.4%), although at lower limits. At the end of 12 weeks of Moringa supplement administration, the results showed subjects in the TDF-M group who were at risk of CVD had fallen to 20%, indicating a dramatic (40.4%) decrease, while the prevalence of TDF-NM subject at risk of CVD rose to 53.6% (χ2=26.67, P <0.001). HIV patients on TDF-based regime, who were at risk of CVD had elevated triglycerides and low-density lipoprotein cholesterols which inversely affected the levels of high-density lipoprotein and negatively impacting the atherogenic indices.

Conclusions: Moringa oleifera supplementation may be helpful in ameliorating the metabolic abnormalities associated with HIV patients on TDF-based regimen.


Human immunodeficiency viruses, Tenofovir disoproxil fumarate, Metabolic abnormalities, M. oleifera

Full Text:



Nath A. Neurologic complications of human immunodeficiency virus infection. Continuum (MinneapMinn). 2015;21(6):1557-6.

World Health Organization (WHO). Global health sector strategy on HIV/AIDS 2011-2015. Geneva: World Health Organization, 2015. Available at Accessed 12 April 2016.

Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999; 353(9170): 2093-9.

Currier JS. Epidemiology of cardiovascular disease and risk factors in HIV-infected patients. Up to date. Walter Kluwer, 2015. Available at: Accessed 12 April 2016.

Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51.

Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther. 2006;13(3):248-60,

Grinspoon SK, Grunfeld C, Kotler DP. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118(2):198-210.

Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol. 2005;95(5):586-91.

Currier JS, Lundgren JD, Carr A. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):29-35.

Dobiasova M. AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Inter Med. 2006;52(1):64-71.

Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583-8.

Castelli WJ, Garrison RJ, Wilson PWF, Abbot RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-8.

Assmann G, Schulte H. The prospective cardiovascular münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116(6 Pt 2):1713-24.

Grover SA, Palmer CS, Coupall L. Serum lipid screening to identify high risk individuals for coronary death: the results of the Lipid Research Clinics prevalence cohort. Arch Intern Med. 1994;154:679-84.

The West of Scotland Coronary Prevention Study Group (WOSCOPS): baseline risk factors and their association with outcome in the West of Scotland coronary prevention study. Am J Cardiol. 1997;79:756-62.

Gotto A, Whitney E, Stein EA, Shapiro DR., Clearfield M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary event in the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Circulation. 2000;101:477-84.

Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81(3):333-5.

Mehta K, Balaraman R, Amin AH, Bafna PA, Gulati OD. Effect of fruits of Moringa oleifera on the lipid profile of normal and hypercholesterolaemic rabbits. J Ethnopharmacol. 2003;86(2-3):191-5.

Gunjal AM, Shah AS, Wakade AS, Juvekar AR. Protective effect of aqueous extract of Moringa oleifera Lam. stem bark on serum lipids, marker enzymes and heart antioxidants parameters in isoproterenol-induced cardiotoxicity in Wistar rats. Ind J Nat Prod Res. 2010;1(4):485-92.

Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Health-related Research Involving Humans. Fourth Edition. Geneva. 2016. Available at: Accessed 7 November 2016.

Junod SW, Beaver WT. FDA and clinical drug trials: a short history. US Food and Drug Administration, 2013. Available at: /Overviews/ucm304485.htm. Accessed 7 May 2016.

Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Brit Med J. 2010;340:c332.

Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder, B, Reitman, D, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2(1):31-49.

Ranjith G. Interferon-α-induced depression: when a randomized trial is not a randomized controlled trial. Psychother Psychosom. 2005;74(6):387.

Li LM, Ye DQ, Zhan SY. Epidemiology. 6th ed. Beijing: People's Medical Publishing House; 2007.

Zhong B. How to calculate sample size in randomized controlled trial. J Thorac Dis. 2009;1(1):51-4.

Nwagha U, Ikekpeazu E, Ejezie F, Neboh E, Maduka I. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr J Health Sci. 2010;10(3):248-52.

Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol. 2006;97(3):372-5.

Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757-65.

Criqui MH, GolomBA. Epidemiologic aspects of lipid abnormalities. Am J Med. 1998;105(1A): 48S-57S.

Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, Ligabue G, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis. 2010;208(1):222-7.

Nsagha DS, Assob JCN, Njunda AL, Tanue EA, Kibu OD, Ayima CW, et al. Risk factors of cardiovascular diseases in HIV/AIDS patients on HAART. Open AIDS J. 2015;9:51-9.

Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the veterans affairs high-density lipoprotein intervention trial. Am J Cardiol. 2000;86(12A):19L-22L.

Assmann G. Pro and con: High-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol. 2001;87(5A):2B-7B.

Brewer HB Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol. 1999;83(9B):3F-12F.

Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M, et al. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es GaSalaam, Tanzania. J Acquir Immune Defic Syndr. 2011;57(2):141-5.

Bloomfield GS, Hogan JW, KeterA, Sang E, Carter EJ, Velazquez EJ, et al. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PLoS One. 2011;6(7):e22288.

Dangi SY, Jolly CI, Narayanan S. Antihypertensive activity of the total alkaloids from the leaves of Moringa oleifera. Pharm Biol. 2002;40:144-8.

Rouhi-Broujeni H, Heidarian E, Darvishzadeh-Boroojeni P, Rafieian-Kopaei M, Gharipour M. Lipid lowering activity of Moringa pergerina seeds in rat: a comparison between the extract and atorvastatin. J Biol Sci. 2013;8(5):150-4.

Bais S, Singh SG, Sharma R. Antiobesity and hypolipidemic activity of Moringa oleifera leaves against high fat diet-induced obesity in rats. Adv Biol. 2014(162914):9.